Transcatheter Valve Replacement Best for Severe Tricuspid Regurgitation

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 4, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Nov. 4, 2024 -- Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid regurgitation, according to a study published online Oct. 30 in the New England Journal of Medicine to coincide with the annual Transcatheter Cardiovascular Therapeutics conference, held from Oct. 27 to 30 in Washington, D.C.

Rebecca T. Hahn, M.D., from the Columbia University Irving Medical Center in New York City, and colleagues randomly assigned 400 patients with severe symptomatic tricuspid regurgitation to undergo transcatheter tricuspid-valve replacement and medical therapy (valve-replacement group) or medical therapy alone (control group; 267 and 133 patients, respectively). All possible patient pairs were compared to calculate the win ratio for the primary outcome.

The researchers found that the win ratio favoring valve replacement was 2.02 at one year. More wins occurred among patients in the valve-replacement group versus the control group with respect to death from any cause (14.8 versus 12.5 percent), postindex tricuspid-valve intervention (3.2 versus 0.6 percent), and improvement in the Kansas City Cardiomyopathy Questionnaire overall summary score (23.1 versus 6.0 percent), New York Heart Association functional class (10.2 versus 0.8 percent), and six-minute walk distance (1.1 versus 0.9 percent). With respect to the annualized rate of hospitalization for heart failure, the valve-replacement group had fewer wins than the control group (9.7 versus 10.0 percent). Severe bleeding occurred in 15.4 and 5.3 percent of the valve-replacement and control groups, respectively.

"In patients with severe tricuspid regurgitation, transcatheter tricuspid-valve replacement plus medical therapy was superior to medical therapy alone," the authors write.

The study was funded by Edwards Lifesciences.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-11-05 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords